Hyperglycemia is the major risk factor for microvascular complications in patients with type 2
diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and …

The US Food and Drug Administration (FDA) issued a diabetes guidance in 2008 mandating
that all new antidiabetes drugs rule out excess cardiovascular (CV) risk, defined as an upper …

Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing
cardiovascular disease (CVD)—namely myocardial infarction, heart failure, and stroke …

Type 2 diabetes mellitus (T2DM) is a recognized risk factor for cardiovascular (CV) disease
(CVD). 1 In a large, prospective, cohort study of individuals> _30years of age, 18% of …

Choices for the treatment of type 2 diabetes mellitus (T2DM) have multiplied as our
understanding of the underlying pathophysiologic defects has evolved. Treatment should …

Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce
events in patients with diabetes and cardiovascular (CV) disease, a group common in …

Aims Recent trials (EMPA-REG OUTCOME and Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results [LEADER]) have shown improved …

Diabetic patients suffer from a high rate of cardiovascular events and such risk increases
with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on …

This review examines recent randomized controlled cardiovascular (CV) outcome trials of
glucose‐lowering therapies in type 2 diabetes and their impact on the treatment of patients …

Patients with type 2 diabetes mellitus (T2D) exhibit an increased risk for cardiovascular (CV)
events. Hyperglycaemia itself contributes to the pathogenesis of atherosclerosis and heart …